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ABSTRACT
Background and objective: Post-bronchodilator (BD)
lung function is recommended for the diagnosis of
chronic obstructive pulmonary disease (COPD). How-
ever, often only pre-BD lung function is used in clinical
practice or epidemiological studies. We aimed to com-
pare the discrimination ability of pre-BD and post-BD
lung function to predict all-cause mortality.
Methods: Participants aged ≥40 years with airflow limi-
tation (n = 2538) and COPD (n = 1262) in the second
survey of the Nord-Trøndelag Health Study (HUNT2,
1995–1997) were followed up until 31 December 2015.
Survival analysis and time-dependent area under the
receiver operating characteristic curves (AUC) were
used to compare the discrimination ability of pre-BD
and post-BD lung function (percent-predicted forced
expiratory volume in the first second (FEV1) (ppFEV1),
FEV1 z-score, FEV1 quotient (FEV1Q), modified Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
categories or GOLD grades).
Results: Among 2538 participants, 1387 died. The AUC
for pre-BD and post-BD ppFEV1 to predict mortality
were 60.8 and 61.8 (P = 0.005), respectively, at 20 years’
follow-up. The corresponding AUC for FEV1 z-score
were 58.5 and 60.4 (P < 0.001), for FEV1Q were 68.7 and
70.1 (P = 0.002) and for modified GOLD categories were
62.3 and 64.5 (P < 0.001). Among participants with COPD,
the AUC for pre-BD and post-BD ppFEV1 were 57.0 and
58.8 (P < 0.001), respectively. The corresponding AUC for
FEV1 z-score were 53.1 and 55.8 (P < 0.001), for FEV1Q
were 63.6 and 65.1 (P = 0.037) and for GOLD grades were
56.0 and 57.0 (P = 0.268).
Conclusion: Mortality was better predicted by post-BD
than by pre-BD lung function; however, they differed
only by a small margin. The discrimination ability using
GOLD grades among COPD participants was similar.
Key words: area under the curve, mortality, post-bronchodila-
tor, pre-bronchodilator, prediction.
INTRODUCTION
According to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), diagnosis and
classification of chronic obstructive pulmonary dis-
ease (COPD) should be based on post-bronchodilator
(BD) spirometric measurements.1 However, post-BD
tests are time-consuming and not performed as fre-
quently as recommended.2,3 Often, only pre-BD lung
function is used in clinical practice or in epidemio-
logical studies. Additionally, only a few studies have
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SUMMARY AT A GLANCE
Few previous studies have compared the discrimi-
nation ability of pre-BD and post-BD lung function
in predicting mortality. We found post-BD is slightly
better than pre-BD to predict mortality using
percent-predicted forced expiratory volume in the
first second (FEV1), FEV1 z-score, FEV1 quotient
(FEV1Q) or modified Global Initiative for Chronic
Obstructive Lung Disease (GOLD) categories. How-
ever, among people with chronic obstructive pul-
monary disease (COPD), mortality was similarly
predicted using GOLD grades.
© 2019 The Authors
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compared mortality associated with both pre-BD and
post-BD lung function.4–6 Mannino et al.6 found simi-
lar mortality prediction for pre-BD and post-BD lung
function in the general population. However, the
area under the receiver operating characteristic curve
(AUC) from logistic models was used to compare
models, and this approach ignores important infor-
mation about time-to-event concerning mortality. In
contrast to Mannino et al.,6 Chen et al.4 and Fortis
et al.5 found post-BD to be better than pre-BD
percent-predicted forced expiratory volume in the
first second (ppFEV1) in predicting mortality. How-
ever, the study by Chen et al.4 included only a limited
number of COPD patients (n = 300) from a pulmo-
nary department and follow-up in both studies was
limited to approximately 5 years.
We aimed to compare the discrimination ability of
pre-BD and post-BD lung function to predict all-cause
mortality in participants with airflow limitation or
COPD selected from a large population-based study
with over 20 years’ follow-up.
METHODS
Study population
The second survey of the Nord-Trøndelag Health
Study (HUNT2, 1995–1997) invited the entire adult
population (≥20 years old) of northern Trøndelag,
Norway, to attend clinical examinations and answer
questionnaires.7
The current study included participants aged
≥40 years in the HUNT2 Study (n = 44 384)7 with air-
flow limitation (pre-BD FEV1/forced vital capacity
(FVC) < 0.75 or FEV1 < 80% of predicted using the
European Coal and Steel Community (ECSC) equa-
tions8) and acceptable pre-BD and post-BD spirometry
manoeuvres (n = 2538) (Fig. S1, Appendix S1 in Sup-
plementary Information).
Ethical approval was obtained from the Regional
Committee for Medical Research Ethics (2015/1461/
REK midt). All participants gave informed written
consent.
Spirometry and lung function classification
Participants performed pre-BD and post-BD (30 min
after inhalation of 1 mg terbutaline) spirometry
according to the 1994 American Thoracic Society (ATS)
guidelines with a heated pneumotachograph spirome-
ter.9,10 Quality assurance of spirometric measurements
is described in detail elsewhere.9,11
The Global Lung Function Initiative (GLI)-2012 refer-
ence equation was used to calculate ppFEV1, percent-
predicted FVC (ppFVC) and to derive FEV1 z-scores
based on lambda–mu–sigma (LMS) methods.9,12 In the
LMS method, the median (Mu) represents how FEV1
changes with age, sex, height and ethnicity; the coeffi-
cient of variation (Sigma) models the spread of refer-
ence values; and the skewness (Lambda) models
departure from normality.12,13 FEV1 was standardized
by sex-specific lowest first percentile (0.5 L for men
and 0.4 L for women) of FEV1 distribution to calculate
the FEV1 quotient (FEV1Q).
14 Pre-BD and post-BD lung
function were classified into modified GOLD categories
as follows: normal (FEV1/FVC ≥ 0.70 and ppFVC ≥ 80),
preserved ratio impaired spirometry (FEV1/FVC ≥ 0.70
and ppFVC < 80), mild obstruction (FEV1/FVC < 0.70
and ppFEV1 ≥ 80), moderate obstruction (FEV1/
FVC < 0.70 and 80 > ppFEV1 ≥ 50), severe obstruction
(FEV1/FVC < 0.70 and 50 > ppFEV1 ≥ 30) and very
severe obstruction (FEV1/FVC < 0.70 and ppFEV1
< 30).1,15
Additionally, a COPD cohort (n = 1262) was defined
as having persistent airflow limitation (pre-BD and
post-BD FEV1/FVC < 0.70) concurrent with respiratory
symptoms or self-reported doctor-diagnosed COPD.1
Respiratory symptoms included daily cough in periods,
cough with phlegm, wheezing and dyspnoea. GOLD
grades were defined as GOLD1 (ppFEV1 ≥ 80), GOLD2
(80 > ppFEV1 ≥ 50), GOLD3 (50 > ppFEV1 ≥ 30) and
GOLD4 (ppFEV1 < 30) in the COPD cohort.
1
Clinical examination and questionnaires
Information on age (years), sex, body mass index
(BMI, kg/m2), smoking status, smoking pack-years,
physical activity, education, diabetes ever, asthma
ever, cardiovascular disease, systolic blood pressure
(mm Hg) and non-fasting total serum cholesterol
(mmol/L) was ascertained from clinical examination
and questionnaires.
Age was recorded to one decimal place. Height
and weight were measured with light clothing and
without shoes, and rounded to the nearest
centimetre or half kilogram, respectively.16,17 Cardio-
vascular disease included self-reported angina
pectoris, myocardial infarction and stroke. Systolic
blood pressure was measured three times and the
mean of the last two measurements was used.17
Follow-up and outcome
HUNT2 participants (1995–1997) were followed up
until death, emigration (n = 6) or 31 December 2015.
The Norwegian Cause of Death Registry provided infor-
mation on date of death.
Statistical analysis
Mortality rates per 1000 person-years with 95% CI were
calculated. We used log-rank test of Kaplan–Meier esti-
mates for mortality.
Cox proportional hazard models were used to calcu-
late hazard ratios (HR) and 95% CI for the associations
of pre-BD and post-BD lung function with mortality.
We presented crude HR (Model 1) and adjusted HR
(Model 2). Model 2 accounted for age (as a continuous
variable), sex (women and men), smoking (never, for-
mer (<10, 10–19 and ≥20 pack-years), current (<10,
10–19 and ≥20 pack-years) and unknown), BMI (<25.0,
25.0–29.9, ≥30.0 and unknown) and education (<10,
≥10 years and unknown). In supplementary analyses,
we additionally adjusted for physical activity (none,
light exercise, hard exercise and unknown), cardiovas-
cular diseases (no, yes and unknown), asthma ever
(no, yes and unknown), diabetes ever (no, yes and
unknown), systolic blood pressure (sex-specific
© 2019 The Authors
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Lung function and mortality 3
quartiles and unknown) and cholesterol (sex-specific
quartiles and unknown) (Model 3).
Multicollinearity was tested where the variance infla-
tion factor (VIF) was less than 1.5 in all models.18,19
Proportional hazard assumptions were evaluated using
log–log survival curves and Schoenfeld residual test.20
As a measure of goodness of fit, we estimated the
Akaike information criteria (AIC) and performed
Gronnesby and Borgan tests for each model (Table S1
in Supplementary Information).21,22
We calculated time-dependent AUC to compare the
discrimination ability of pre-BD and post-BD lung
function to predict mortality.23–26 The incident/dynamic
(I/D) AUC models account for incident cases at time t
and dynamic controls, which means it characterizes
the time-varying performance without selecting a par-
ticular timeframe over which cases accrue, whereas
cumulative/dynamic (C/D) AUC models account for
cumulative cases at time t and dynamic controls.25,27
We compared the AUC for crude models because the
clinical decision usually does not explicitly take other
factors into account.14,28 Additionally, as a global mea-
sure of informativeness, we calculated concordance
index (C-index).25 We used 10 000 bootstrap iterations
to calculate 95% CI for I/D AUC and C-index.27 A gen-
eral bootstrap algorithm (gBA) was applied to compare
the I/D AUC and C-index.29
We performed all the analyses both among partici-
pants with airflow limitation and among participants
with COPD. Statistical analysis was performed using R
3.5.0 (http://www.r-project.org) and Stata 15.1
(StataCorp., College Station, TX, USA).
RESULTS
In the cohort of participants with airflow limitation, the
median and maximum follow-up times were 17.8 and
20.4 years, respectively. Based on pre-BD lung function
at baseline, 27.9% had normal lung function and 1.8%
had very severe obstruction. Corresponding propor-
tions for post-BD lung function were 37.3% and 0.7%,
respectively (Table 1). The distribution of participants
between pre-BD and post-BD modified GOLD catego-
ries is presented in Table S2 in Supplementary
Information.
A trend for increasing age, smoking pack-years,
physical inactivity and mortality rates, and decreasing
education and BMI with worsening modified GOLD
categories was observed for both pre-BD and post-BD
lung function (Table 1, Table S3 in Supplementary
Information). We observed a similar increasing trend of
mortality in unadjusted cumulative incidence curves
(Fig. S2 in Supplementary Information).
A 10% reduction in ppFEV1 and 1-unit reduction in
FEV1 z-score and FEV1Q were associated with 19%,
36% and 33% increased risk of death, respectively,
using pre-BD lung function. Similarly, worsening modi-
fied GOLD categories were associated with increased
risk of death. Results were similar for post-BD lung
function (Table 2, Model 2), in Model 3 (Table S4 in
Supplementary Information) and among participants
with COPD (Table S5 in Supplementary information).
The I/D AUC (95% CI) for pre-BD and post-BD
ppFEV1 were 60.8 (59.3–62.2) and 61.8 (60.2–63.4),
respectively, for mortality at 20 years’ follow-up
Table 2 HR for pre-BD and post-BD lung function among participants aged ≥40 years with airflow limitation in the
HUNT2 Study (1995–1997)
Lung function†,‡,§,¶ (n = 2538)
Pre-BD Post-BD
Model 1 Model 2 Model 1 Model 2
HR (95% CI)†† HR (95% CI)‡‡ HR (95% CI)†† HR (95% CI)‡‡
ppFEV1
¶ 1.28 (1.24–1.31) 1.19 (1.16–1.22) 1.31 (1.27–1.34) 1.22 (1.19–1.25)
FEV1 z-score
§ 1.31 (1.26–1.37) 1.36 (1.30–1.42) 1.40 (1.34–1.45) 1.41 (1.35–1.48)
FEV1Q
‡ 1.67 (1.61–1.73) 1.33 (1.27–1.39) 1.72 (1.66–1.78) 1.38 (1.32–1.44)
Modified GOLD categories† Normal 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
PRISm 2.33 (1.85–2.94) 1.79 (1.41–2.26) 2.59 (2.08–3.24) 1.95 (1.56–2.45)
Mild obstructive 1.77 (1.47–2.12) 1.17 (0.98–1.41) 2.12 (1.80–2.50) 1.16 (0.98–1.37)
Moderate obstructive 2.78 (2.38–3.25) 1.78 (1.52–2.08) 3.20 (2.78–3.69) 1.86 (1.60–2.15)
Severe obstructive 5.23 (4.32–6.33) 2.77 (2.27–3.37) 6.59 (5.41–8.02) 3.44 (2.80–4.23)
Very severe obstructive 7.00 (5.02–9.75) 5.03 (3.57–7.08) 6.00 (3.73–9.67) 4.68 (2.89–7.59)
†Normal: FEV1/FVC ≥ 0.70 and ppFVC ≥ 80; PRISm: FEV1/FVC ≥ 0.70 and ppFVC < 80; mild obstructive: FEV1/FVC < 0.70 and
ppFEV1 ≥ 80; moderate obstructive: FEV1/FVC < 0.70 and 80 > ppFEV1 ≥ 50; severe obstructive: FEV1/FVC < 0.70 and 50 > ppFEV1 ≥ 30;
very severe obstructive: FEV1/FVC < 0.70 and ppFEV1 < 30.
‡FEV1 standardized by sex-specific lowest first percentile (0.5 L for men and 0.4 L for women) of FEV1 distribution. HR were for a
1-unit reduction in FEV1Q.
§FEV1 z-score based on GLI-2012 equation. HR were for a 1-unit reduction in FEV1 z-score.
¶ppFEV1 based on GLI-2012 equation. HR were for a 10% reduction in ppFEV1.
††Crude model.
‡‡Adjusted for age, sex, smoking, body mass index and education.
BD, bronchodilator; FEV1, forced expiratory volume in the first second; FEV1Q, FEV1 quotient; FVC, forced vital capacity; GLI, Global
Lung Function Initiative; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; HUNT2, the second survey of
the Nord-Trøndelag Health Study (1995–1997); ppFEV1, percent-predicted FEV1; ppFVC, percent-predicted FVC; PRISm, preserved ratio
impaired spirometry.
© 2019 The Authors
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(P = 0.005) (Table 3, Fig. 1, Fig. S3 in Supplementary
Information). A similar pattern was observed over
time (Fig. 1). Corresponding estimates for FEV1 z-
score were 58.5 (57.0–59.9) and 60.4 (58.8–62.0)
(P < 0.001), for FEV1Q were 68.7 (66.8–70.5) and 70.1
(68.1–72.1) (P = 0.002) and for modified GOLD cate-
gories were 62.3 (60.6–63.8) and 64.5 (62.9–66.1)
(P < 0.001) (Table 3,Fig. 1,Fig. S3 in Supplementary
Information).
Among participants with COPD, the I/D AUC (95%
CI) for pre-BD and post-BD ppFEV1 were 57.0
(55.1–58.8) and 58.8 (56.7–60.8), respectively, for
predicting mortality at 20 years’ follow-up (P < 0.001)
and results were similar over time (Fig. 2, Table S6 in
Supplementary Information). Corresponding esti-
mates for FEV1 z-score were 53.1 (95% CI: 51.5–54.8)
and 55.8 (95% CI: 53.9–57.7) (P < 0.001), for FEV1Q
were 63.6 (95% CI: 60.9–65.9) and 65.1 (95% CI:
62.0–67.9) (P = 0.037) and for GOLD grades were 56.0
(95% CI: 53.9–57.9) and 57.0 (95% CI: 54.6–59.2)
(P = 0.268) (Fig. 2, Table S6 in Supplementary
Information).
The results from C-index and C/D AUC (Tables S6,
S7, Figs S4, S5 in Supplementary Information) were
generally in agreement with I/D AUC.
DISCUSSION
In this large population-based study of participants
with airflow limitation, mortality was slightly better
predicted by post-BD than by pre-BD lung function
whether using ppFEV1, FEV1 z-score, FEV1Q or modi-
fied GOLD categories. Among participants with COPD,
the discrimination ability of post-BD was slightly higher
than pre-BD to predict mortality using ppFEV1, FEV1
z-score or FEV1Q but the discrimination ability using
GOLD grades was similar.
Similar to our study, other studies have found that
decreased ppFEV1, FEV1 z-score or FEV1Q are associ-
ated with an increased risk of death.6,14,30,31 Furthermore,
a study by Mannino et al.32 found that the risk of death
increased with worsening GOLD-defined airflow limita-
tion, where participants with severe or very severe
obstruction were associated with 4.5 times higher risk of
dying compared to participants with normal lung func-
tion. HR were slightly higher than in our study, likely
due to the exclusion of participants with respiratory
symptoms from their reference population.32
The discrimination ability of pre-BD and post-BD
lung function to predict mortality was generally poor
except for FEV1Q which had fair discrimination abil-
ity.33 Nevertheless, we found that mortality was better
predicted by post-BD than by pre-BD lung function at
20 years’ follow-up, and this was consistent over time
in models using ppFEV1, FEV1 z-score, FEV1Q or modi-
fied GOLD categories. There are no previous studies
directly comparing the discrimination ability of pre-BD
and post-BD lung function as a predictive marker of
mortality when other predictors are not taken into con-
sideration and no studies have included measurements
of FEV1 z-score and FEV1Q. However, in a study by
Fortis et al.5 that followed up 8221 adults for approxi-
mately 6.5 years, post-BD was a stronger predictor for
mortality than pre-BD lung function in models adjusted
with covariates. We found similar results in our study
at 6.5 years’ follow-up for mortality in both crude and
adjusted models (P < 0.001 for both, results not
shown). Additionally, one study investigated 5887
adults from the general population participating in
NHANES and compared the predictive ability of pre-
BD and post-BD lung function for mortality after
20 years.6 In this study, Mannino et al.6 found that pre-
BD and post-BD lung function similarly predicted mor-
tality where the AUC for pre-BD and post-BD ppFEV1
were 69.2 and 69.4, respectively, and for pre-BD and
post-BD modified GOLD categories the AUC were 69.2
and 69.6, respectively. Compared to our study, this
study included other predictors of mortality and AUC
were calculated from logistic regression models, which
do not take account of time-to-event.6 However, at
20 years’ follow-up, when we included other predictors
of mortality in our models the results were similar to
Mannino et al.6 (Table S8 in Supplementary Informa-
tion). This suggests that when other factors are consid-
ered, including post-BD lung function in models might
not be more informative than pre-BD lung function at
predicting long-term mortality.
Among participants with COPD, mortality was better
predicted by post-BD ppFEV1, FEV1 z-score and FEV1Q
Table 3 I/D time-dependent AUC for pre-BD and
post-BD lung function at 20 years of follow-up among
participants aged ≥40 years with airflow limitation in the
HUNT2 Study (1995–1997)
Lung
function†,‡,§,¶
(n = 2538)
Pre-BD Post-BD
P-
value
Model 1 Model 1
I/D AUC
(95% CI)††
I/D AUC
(95% CI)††
ppFEV1
¶ 60.8 (59.3–62.2) 61.8 (60.2–63.4) 0.005
FEV1 z-score
§ 58.5 (57.0–59.9) 60.4 (58.8–62.0) <0.001
FEV1Q
‡ 68.7 (66.8–70.5) 70.1 (68.1–72.1) 0.002
Modified
GOLD
categories†
62.3 (60.6–63.8) 64.5 (62.9–66.1) <0.001
†Normal: FEV1/FVC ≥ 0.70 and ppFVC ≥ 80; PRISm: FEV1/
FVC ≥ 0.70 and ppFVC < 80; mild obstructive: FEV1/FVC < 0.70
and ppFEV1 ≥ 80; moderate obstructive: FEV1/FVC < 0.70 and
80 > ppFEV1 ≥ 50; severe obstructive: FEV1/FVC < 0.70 and
50 > ppFEV1 ≥ 30; very severe obstructive: FEV1/FVC < 0.70
and ppFEV1 < 30.
‡FEV1 standardized by sex-specific lowest first percentile
(0.5 L for men and 0.4 L for women) of FEV1 distribution.
§FEV1 z-score based on GLI-2012 equation.
¶ppFEV1 based on GLI-2012 equation.
††The Cox model included pre-BD or post-BD lung function.
AUC, area under the receiver operating characteristic
curve; BD, bronchodilator; FEV1, forced expiratory volume in
the first second; FEV1Q, FEV1 quotient; FVC, forced vital
capacity; GLI, Global Lung Function Initiative; GOLD, Global
Initiative for Chronic Obstructive Lung Disease; HUNT2, the
second survey of the Nord-Trøndelag Health Study
(1995–1997); I/D, incident/dynamic; ppFEV1, percent-predicted
FEV1; ppFVC, percent-predicted FVC; PRISm, preserved ratio
impaired spirometry.
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than by pre-BD ppFEV1, FEV1 z-score and FEV1Q,
respectively, at 20 years’ follow-up. Over time, the dif-
ference was constant for pre-BD and post-BD ppFEV1,
post-BD FEV1 z-score or post-BD FEV1Q. However, for
GOLD grades, the discrimination ability was similar at
20 years’ follow-up and this pattern was constant over
time. To our knowledge, no other studies have com-
pared pre-BD and post-BD lung function using FEV1
z-score or FEV1Q, and only one study has compared
pre-BD- and post-BD-defined GOLD grades in
predicting mortality among participants with COPD.4 In
contrast to our study, Chen et al.4 found that mortality
was better predicted by post-BD than by pre-BD lung
function after 51 months (approximately 4 years) of
follow-up among 300 COPD patients from a pulmonary
department. The discrimination ability for mortality
was compared between pre-BD and post-BD GOLD
grades using log-rank tests (Kaplan–Meier estimates)
where respective models had P = 0.131 and P = 0.009.4
The disagreement between Chen et al.4 and our study
might be due to methodological differences between
studies (log-rank method vs time-dependent AUC used
in our study).
BD dilate bronchi and bronchioles to reverse the
airflow limitation. In COPD, airflow limitation is vari-
able and primarily irreversible where use of BD fea-
tures small reversible components.34 GOLD guidelines
recommend post-BD spirometry for the classification of
COPD.1 It is also reported that lung function reference
values for post-BD differ from pre-BD spirometry in the
general population.35 However, often, only pre-BD lung
function is used in clinical practice or in epidemiologi-
cal studies. Therefore, to compare which measure best
predicts mortality is an important question for respira-
tory medicine. In our study, we observed that mortality
was better predicted by post-BD than by pre-BD lung
function among participants with airflow limitation, by
a margin of approximately 2%. This potential gain in
discrimination ability, if replicated in other studies,
should be evaluated against the cost and clinical signif-
icance of such measurements in this subgroup of indi-
viduals. Among participants with COPD, mortality did
not seem to be better predicted by post-BD-defined
GOLD grades than by pre-BD. This study could have
clinical implications as to how procedures might be
prioritized in different subgroups.
This study had several strengths. It is the first study
to investigate the discrimination ability of pre-BD and
post-BD lung function over a 20-year period to predict
mortality using FEV1 z-score and FEV1Q. The study is
based on the HUNT2 Lung Study which had a reason-
ably high level of participation (76.0% of invited Lung
Study population), which limits potential selection bias.
We had complete information on mortality and there
Figure 1 Incident/dynamic time-dependent area under the receiver operating characteristic curve (AUC) for pre-bronchodilator
(BD) ( ) and post-BD ( ) (A) percent-predicted forced expiratory volume in the first second (FEV1), (B) FEV1 z-score, (C) FEV1 quo-
tient (FEV1Q) and (D) modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories for all-cause mortality change
over follow-up time (years) among participants aged ≥40 years with airflow limitation in the second survey of the Nord-Trøndelag
Health Study (HUNT2, 1995–1997).
© 2019 The Authors
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was no loss to follow-up other than very few emigra-
tions (6 out of 2538 participants). To reduce measure-
ment error, quality assurance of spirometry curves was
performed.9,11
This study however had certain limitations. Partici-
pants with airflow limitation from the HUNT2 Lung
Study were included; therefore, these findings may not
necessarily apply to the general population. Addition-
ally, there was missing information on some covariates;
therefore, to avoid sample loss in adjusted models, a
missing indicator variable (missing information as
unknown category) was used which might bias the
association between lung function and mortality. The
HUNT population is homogeneous; therefore, general-
izability of findings outside a non-Caucasian popula-
tion might be limited.
In summary, we found that mortality was better
predicted by post-BD than by pre-BD lung function;
however, they differed only by a small margin. The dis-
crimination ability using GOLD grades among COPD
participants was similar. The clinical significance of the
findings in daily handling of patients should be studied
further.
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Figure S1 Flow chart: pre-bronchodilator (BD) and post-BD spirometry among people aged ≥40 years in the HUNT2 Study.
Figure S2 Cumulative incidence curves of all-cause mortality for pre-bronchodilator (BD) and post-BD modified GOLD categories
among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Figure S3 Incident/dynamic time-dependent ROC curve (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted
forced expiratory volume in the first second (FEV1), (B) FEV1 z-score, (C) FEV1Q and (D) modified GOLD categories for all-cause
mortality at 20 years’ follow-up time among participants aged ≥40 years with airflow limitation in the HUNT2 study (1995–1997).
Figure S4 Cumulative/dynamic time-dependent AUC (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted forced
expiratory volume in the first second (FEV1), (B) FEV1 z-score, (C) FEV1Q and (D) modified GOLD categories for all-cause mortality
change over follow-up time (years) among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Figure S5 Cumulative/dynamic time-dependent AUC (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted forced
expiratory volume in the first second (FEV1), (B) FEV1 z-score, (C) FEV1Q and (D) GOLD grades for all-cause mortality change over
follow-up time (years) among participants aged ≥40 years with COPD in the HUNT2 Study (1995–1997).
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Table S2 Pre-bronchodilator (BD) and post-BD modified GOLD categories of participants aged ≥40 years with airflow limitation in the
HUNT2 Study (1995–1997).
Table S3Mortality rate for pre-bronchodilator (BD) and post-BD modified GOLD categories among participants aged ≥40 years with
airflow limitation in the HUNT2 Study (1995–1997).
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limitation in the HUNT2 Study (1995–1997).
Table S5 Hazard ratios for pre-bronchodilator (BD) and post-BD lung function among participants aged ≥40 years with COPD in the
HUNT2 Study (1995–1997).
Table S6 Incident/dynamic time-dependent area under the receiver operating characteristic curve (AUC), C-index and
cumulative/dynamic time-dependent AUC for pre-bronchodilator (BD) and post-BD lung function at 20 years of follow-up among
participants aged ≥40 years with COPD in the HUNT2 Study (1995–1997).
Table S7 C-index and cumulative/dynamic time-dependent AUC for pre-bronchodilator (BD) and post-BD lung function at 20 years of
follow-up among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
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among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
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